# OnCo record fostamatinib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/fostamatinib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "fostamatinib" ;
  schema:name "Fostamatinib"@en ;
  schema:alternateName "Fostamatinib Disodium"@en, "R788"@en, "R935788"@en, "Tavalisse" ;
  schema:description "Fostamatinib is a tablet that blocks the enzyme SYK so the spleen stops destroying antibody-coated platelets; it is approved for chronic immune thrombocytopenia and was first trialled as a lymphoma drug."@en ;
  schema:url <https://onco.cc/drugs/fostamatinib/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Fostamatinib> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=fostamatinib>, <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209299> ;
  onco:status "established" ;
  onco:tag "gap-fill", "supportive-care" ;
  onco:modality "Oral spleen tyrosine kinase (SYK) inhibitor" ;
  onco:approval "US 2018: Chronic immune thrombocytopenia in adults with insufficient response to a previous treatment" ;
  onco:cancers <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/fronts/supportive-care/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:companies <https://onco.cc/companies/rigel-pharmaceuticals/> ;
  onco:terms <https://onco.cc/terms/thrombocytopenia/> ;
  onco:trials <https://onco.cc/trials/nct01499303/>, <https://onco.cc/trials/nct00923481/>, <https://onco.cc/trials/nct04543279/> .